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Abstract
Background: Recently, a small population of cancer stem cells in adult and pediatric brain tumors
has been identified. Some evidence has suggested that CD133 is a marker for a subset of leukemia
and glioblastoma cancer stem cells. Especially, CD133 positive cells isolated from human
glioblastoma may initiate tumors and represent novel targets for therapeutics. The gene expression
and the drug resistance property of CD133 positive cancer stem cells, however, are still unknown.
Results: In this study, by FACS analysis we determined the percentage of CD133 positive cells in
three primary cultured cell lines established from glioblastoma patients 10.2%, 69.7% and 27.5%,
respectively. We also determined the average mRNA levels of markers associated with neural
precursors. For example, CD90, CD44, CXCR4, Nestin, Msi1 and MELK mRNA on CD133
positive cells increased to 15.6, 5.7, 337.8, 21.4, 84 and 1351 times, respectively, compared to
autologous CD133 negative cells derived from cell line No. 66. Additionally, CD133 positive cells
express higher levels of BCRP1 and MGMT mRNA, as well as higher mRNA levels of genes that
inhibit apoptosis. Furthermore, CD133 positive cells were significantly resistant to
chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide
(VP16) compared to autologous CD133 negative cells. Finally, CD133 expression was significantly
higher in recurrent GBM tissue obtained from five patients as compared to their respective newly
diagnosed tumors.
Conclusion: Our study for the first time provided evidence that CD133 positive cancer stem cells
display strong capability on tumor's resistance to chemotherapy. This resistance is probably
contributed by the CD133 positive cell with higher expression of on BCRP1 and MGMT, as well as
the anti-apoptosis protein and inhibitors of apoptosis protein families. Future treatment should
target this small population of CD133 positive cancer stem cells in tumors to improve the survival
of brain tumor patients.
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Background
Recently, we and other groups have identified a small
population of cancer stem cells in adult and pediatric
brain tumors [1-4]. These cancer stem cells form neuro-
spheres and possess the capacity for self-renewal. They
also express genes associated with neural stem cells
(NSCs) and differentiate into phenotypically diverse pop-
ulations including neuronal, astrocytic and oligodendro-
glial cells. The novel cell-membrane protein CD133, has
been identified as a marker of a subset of neural stem cells
in the adult central nervous system as well as of glioblast-
oma stem-like cells [1,3]. CD133 positive cancer stem
cells have a capacity for unlimited self-renewal, as well as
the ability to initiate and drive tumor progression in an
animal model [1].
We hypothesized that CD133 positive cancer stem cells
are likely to share many of the properties of normal stem
cells that provide for a long lifespan, including: relative
quiescence; resistance to drugs and toxins through the
expression of several ABC transporters; an active DNA-
repair capacity; and resistance to apoptosis [5]. Bearing
properties of normal neural stem cells, we inferred that
these cancer stem-like cells may not only give us insight
into oncogenesis of glioblastoma but also explain clinical
resistance of these tumors to conventional chemothera-
peutic agents. Clinically it is observed that tumors
respond to chemotherapies only to recur with renewed
resilience and aggression. Although chemotherapy kills
most of the cells in a tumor, cancer stem cells may be left
behind, which then recur be an important due to their
chemoresistance. In this study, for the first time we pro-
vided evidence that CD133 positive cancer stem cells dis-
play significant resistance to conventional
chemotherapeutic agents. These features may be corre-
lated to the overexpression of drug resistance genes such
as BCRP1 and DNA-mismatch repair genes such as
MGMT, as well as genes related to inhibiting cell apopto-
sis on CD133 positive cancer stem cells. Furthermore, we
show that CD133 gene expression is significantly higher
in the recurrent GBM tumor tissue from five patients as
compared to their respective newly diagnosed tumors.
These data suggest that CD133 positive cancer stem cells
are resistant to current chemotherapy and may represent a
cell target for novel glioblastoma therapies.
Results
Isolation of CD133 positive cancer stem cells
Recently, CD133 has been identified as a marker of the
subset of glioblastoma stem cells [1,3]. In this study, after
screening thirty glioblastoma patients' primary cultured
cells, we found that three glioblastoma patients' tumor
cells (No. 66, No. 377 and No. 1049) could form separate
colonies in 10% FBS/DMEM/F-12 culture medium for 3–
6 passages (Fig 1A), which in turn became floating neuro-
spheres when switching to serum-free medium containing
EGF/FGF (NSC medium). Based on our previous report
on the characterization of cancer stem cells [2], we
assumed some cancer stem cells might have existed in
these three primary cultured cells. Because CD133 has
been identified as a powerful cancer stem cell marker, we
then examined and found CD133 expression that on
these three primary cultured cell lines in 10% FBS/
DMEM/F-12 medium represented 10.2%, 69.7% and
27.5% of the total population examined on No. 1049,
No. 377 and No. 66, respectively, by flow cytometry anal-
ysis (Fig. 2). We utilized FACS sorting to isolate CD133
positive and CD133 negative cells from the above three
primary cultured cell lines to analyze gene expression and
chemoresistance of these two populations. In addition,
single isolated CD133 positive cancer stem cell was dem-
onstrated to have the capacity for self-renewal and clono-
genic potential (Fig. 1B) and sustain expression of CD133
in NSC medium (Fig. 1C).
Expression of markers associated with neural precursors 
on CD133 positive tumor cells
It has been demonstrated that tumors contain CD133
positive cells and that such cells drive tumor progression
[1]. The expression of other genes related to cell "stem-
ness" on CD133 positive cells, however, is still unknown.
Therefore, we collected the CD133 positive cells and
CD133 negative cells by FACS sorting from the three pri-
mary cultured cells (No. 66, No. 377 and No. 1049) and
used real-time PCR to analyze some markers associated
with neural precursors in these two populations. The
results were shown as in Table 1 section A. For example,
we found that CD90, CD44, CXCR4, Nestin, Musashi-1
(Msi1) and maternal embryonic leucine zipper kinase
(MELK) mRNA expression on CD133 positive cancer stem
cells derived from No. 66 increased an average of 15.6,
5.7, 337.8, 21.4, 84, 1351 times, respectively, compared
to the levels on autologous CD133 negative tumor cells.
In addition, we found that mRNA levels for GLI1 and
PTCH increased an average of 46 and 16 times, respec-
tively, in CD133 positive cells compared to autologous
CD133 negative cells derived from No.66. Similar results
were also found in both No. 377 and No. 1049 cell lines
(Table 1, section A). Furthermore, we found Bmi-1, phos-
phoserine phosphatase (PSP), SHH, OCT4 and Snail
mRNA expressed in CD133 positive cells derived from
above three cell lines, however, none of the five genes
were detectable on CD133 negative cells (data not
shown).
Drug sensitivity of CD133 positive cancer stem cells
At a fundamental level, cancer is resilient to treatment
because malignant cells survive chemotherapy and radia-
tion, or avoid the immune surveillance of endogenous
cytotoxic T cells and natural killer cells. Cancer stem cellsMolecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
Page 3 of 12
(page number not for citation purposes)
Primary culture of adult glioblastoma cells Figure 1
Primary culture of adult glioblastoma cells. (A) Tumor cells looking like neurosphere were found in three glioblastoma 
primary cultured cell lines in 10% FBS/DMEM/F-12 medium. (B) Neurosphere derived from a single isolated CD133 positive 
cell cultured in NSC medium. (C) CD133 expression on neurospheres derived from a single isolated CD133 positive cell in 
NSC medium. Red staining indicates CD133 positive. (Magnification = ×100).Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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have a capacity for unlimited self-renewal, as well as the
ability to initiate and drive tumor progression in an ani-
mal model [1]. We hypothesized that CD133 positive
cells, representing the small population of cancer stem
cells, would demonstrate resistance to traditional chemo-
therapeutic agents. In order to test this hypothesis, WST-1
Cell Proliferation Assay was used to examine the drug sen-
sitivity of CD133 positive cells and CD133 negative cells,
which were collected by FACS sorting from the three pri-
mary cultured cells (No. 66, No. 377 and No. 1049). Both
CD133 positive and negative cells were exposed to con-
ventional chemotherapeutic agents, temozolomide, car-
boplatin, VP16 or Taxol at various concentrations, for up
to 48 hours in 10% FBS/DMEM/F-12 medium. We found
that CD133 positive cells isolated from the above three
cell lines showed dramatic drug resistance to the four
agents including temozolomide, carboplatin, VP16 and
Taxol at different concentrations compared to autologous
CD133 negative cells. One representative experiment on
each primary cultured cell line was shown in Fig. 3, Fig. 4
and Fig. 5, respectively.
Expression of genes related to drug resistance and 
inhibiting cell apoptosis
In order to address the mechanism of CD133 positive
tumor cells showing strong resistance to chemotherapeu-
tic drugs, both CD133 positive cells and CD133 negative
were collected by FACS sorting from the three primary cul-
tured cells (No. 66, No. 377 and No. 1049) and used real-
time PCR to investigate the expression of multi-drug
resistance and DNA mismatch repair related genes, as well
as genes related to inhibiting cell apoptosis within these
two populations. BCRP1 has been demonstrated to play
an important role in the drug resistance of normal stem
cells and tumor stem cells [6,7]. In addition, the presence
of the DNA repair protein MGMT has been demonstrated
to render cells resistant to cytotoxic actions of methylating
and chloroethylating agents, such as temozolomide [8,9].
As shown in Table 1 section B, for example, the average
level of BCRP1 and MGMT was increased to 6.5 and 32.4
times in CD133 positive cells from No.66 when com-
pared to those of autologous CD133 negative cells,
respectively. Furthermore, anti-apoptotic genes, including
CD133 protein expression on primary cultured cells Figure 2
CD133 protein expression on primary cultured cells. Tumor cells were cultured in 10% FBS/DMEM/F-12 medium for 
3–6 passages and stained with specific mAb to CD133, and isotype control-matched mAb. Results are given as the percentage 
of CD133 positive cells in the total population. In the histograms, the thick green line represents staining with CD133 mAb, 
and the gray lines represent the isotype control-matched mAb.Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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FLIP, BCL-2 and BCL-XL, were also found at significantly
higher levels in CD133 positive cells than in autologous
CD133 negative cells (e.g. average 294, 13.9 and 5.6 times
increase in CD133 positive cells from No.66, respec-
tively). The inhibitor of apoptosis protein (IAPs) family
blocks cell death. IAP family members, XIAP, cIAP1,
cIAP2, NAIP and survivin are found at higher expression
levels on CD133 positive cells than those in CD133 nega-
tive cells (e.g. average 21.9, 39.0, 3.0, 12.1, and 1.6 times
increase in CD133 positive cells from No.66, respec-
tively). It has been demonstrated that SIRT1 deacetylates
the DNA repair factor Ku70, causing it to sequester the
pro-apoptotic factor, BAX, away from mitochondria,
thereby inhibiting stress-induced apoptotic cell death
[10]. SIRT1 deacetylase mRNA expression is increased
average 4.9 times, however, the pro-apoptotic gene BAX is
decreased about 3 times in CD133 positive cells from
No.66 when compared to autologous CD133 negative
cells. Overall, the patterns of gene expression are very sim-
ilar in CD133 positive cells derived from both cell lines
from No. 377 and No. 1049. These results were consistent
and supportive with the results of chemoresistance, which
CD133 positive cells showed significant resistance to four
common chemotherapeutic drugs compared to autolo-
gous CD133 negative cells.
Analysis of CD133 expression on glioblastoma tumor tissue
Malignant glioma is a highly recurrent tumor even after
surgery, chemotherapy, radiation and immunotherapy.
We hypothesized that there is a small population of can-
cer stem cells that are resistant to current glioblastoma
therapies and play a very important role in tumor recur-
rence. We further hypothesized that recurrent tumors
should contain more cancer stem cells than primary
tumor, because recurrent tumors are relatively resistant to
currently available therapies. In order to address the
potential role of CD133 positive tumor cells in glioblast-
oma recurrence, we compared the CD133 expression
upon first and second resection of tumor tissue from the
same patient. Five pathological confirmed grade IV astro-
cytoma (GBM) patients underwent an initial operation at
our institution to obtain the primary tumor tissue, then
re-operation following radiation, chemotherapy, and/or
immunotherapy to obtain recurrent tumor tissue. As Fig.
6 shows, for all tested patients, CD133 expression was sig-
nificantly higher in recurrent tumor tissue than that in
autologous primary tumor tissue, respectively.
Discussion
Although the biological function of CD133 is not well
understood, the CD133 currently serves as a useful marker
for the isolation of brain cancer stem cells [1,3]. The iden-
Table 1: Different gene mRNA expression on CD133+ cells compared to those on autologous CD133- cells *
No. 66 No. 377 No. 1049
Section Gene name CD133- CD133+ CD133- CD133+ CD133- CD133+
A CD90 1 15.6 ± 0.66 1 12.8 ± 0.94 1 13.5 ± 0.75
CD44 1 5.7 ± 0.48 1 2.5 ± 0.22 1 2.8 ± 0.19
CXCR4 1 337.8 ± 29.2 1 251.5 ± 22.1 1 264.9 ± 22.9
Nestin 1 21.4 ± 1.25 1 23.2 ± 1.65 1 22.1 ± 1.54
MSI 1 84 ± 7.6 1 75.4 ± 7.03 1 53.5 ± 6.2
MELK 1 1351 ± 95.8 1 467.7 ± 40.5 1 514.6 ± 45.6
GLI-1 1 46 ± 3.8 1 43 ± 4.5 1 49 ± 5.9
PTCH 1 16 ± 1.48 1 13.5 ± 0.85 1 14.3 ± 1.24
B MGMT 1 32.4 ± 2.5 1 34.7 ± 2.9 1 56.3 ± 4.2
BCRP1 1 6.5 ± 0.43 1 4.3 ± 0.25 1 4.8 ± 0.24
SIRT1 1 4.9 ± 0.34 1 4.2 ± 0.26 1 5.4 ± 0.29
FLIP 1 294 ± 25.5 1 157.6 ± 14.2 1 145.6 ± 13.7
BCL-2 1 13.9 ± 0.95 1 4.9 ± 0.54 1 3.8 ± 0.54
BCL-XL 1 5.6 ± 0.39 1 3.2 ± 0.16 1 2.5 ± 0.14
cIAP1 1 39.0 ± 3.5 1 4.3 ± 0.53 1 5.6 ± 0.65
cIAP2 1 3 ± 0.25 1 1.9 ± 0.12 1 1.7 ± 0.14
XIAP 1 21.9 ± 2.2 1 9.7 ± 0.68 1 10.3 ± 0.91
NAIP 1 12.1 ± 0.75 1 6.4 ± 0.43 1 4.5 ± 0.62
Survivin 1 1.6 ± 0.08 1 2.3 ± 0.18 1 2.4 ± 0.18
BAX 1 0.33 ± 0.03 1 0.49 ± 0.06 1 0.21 ± 0.05
* Total RNA was extracted from both CD133+ and CD133- fraction after FACS sorting from three primary cultured cells (No. 66, 377 and 1049). 
Different gene mRNA expression was measured by real-time qPCR. The relative mRNA expression of different gene in CD133+ cells was 
presented as the fold increase compared to that of autologous CD133- cells (see Methods). Data was presented as Mean ± SD of three 
independent experiments.Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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tification of brain cancer stem cells provides a powerful
tool for the investigation of the tumorigenic process in the
central nervous system, and will be crucial in developing
therapies that use brain cancer stem cells as a target [11].
Our data indicated that a large number of CD133 positive
cancer stem cells could be maintained without differenti-
ation in 10% FBS culture medium after 3–6 passages.
Recently, Kondo and his colleagues found that C6, an
established malignant murine glioma cell line (which has
been maintained for years in culture) contained a subpop-
ulation of cancer stem cells [12]. Furthermore, a distinct
"side population" of cells with high drug efflux capacity
were also found in the human glioblastoma cell line U-87,
which is consistent with the findings of the study of C6
glioma cells [7]. We propose that a minor subpopulation
of cancer stem cells derived from glioblastoma tumor tis-
sue may be maintained even in FBS containing medium
which may be a significant character of cancer stem cells
from normal stem cells.
Recent studies show that cancer and normal stem cells
share the same self-renewal mechanisms, such as the Bmi-
1 and Wnt canonical pathways [13,14]. In the present
study, we found thatCD133 positive cells expressed
higher levels of CD90, CD44, Nestin, Msi1, MELK, GLI1
and PTCH. Particularly, Bmi-1, PSP, SHH, OCT4 and
Snail were only expressed on CD133 positive cells; none
Drug sensitivity of CD133 positive cancer stem cells derived from No. 66 Figure 3
Drug sensitivity of CD133 positive cancer stem cells derived from No. 66. Both CD133 positive (CD133+) and 
CD133 negative (CD133-) tumor cells were collected from No. 66 by FACS sorting. 1 × 104 cells/well were plated in 96-well 
plate and treated with various concentrations of temozolomide, carboplatin, Taxol and VP16 for 48 hours in FBS/DMEM/F-12 
medium. * indicates p < 0.05 compared to autologous CD133- cells. Data are representative of two independent experiments.Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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of the five genes were detectable on CD133 negative
tumor cells. The data suggests that these genes involved in
self-renewal are expressed in CD133 positive cancer stem
cells while not in CD133 negative cells. However, Hem-
mati et al. examined mRNA expression profiles of differ-
entiated and undifferentiated spheres from six different
brain tumours and found higher levels of musashi-1,
Sox2, MELK, PSP, Bmi-1, and Nestin were not strictly
associated with the undifferentiated spheres but differed
strongly among the different specimens and these genes
were sometimes even stronger expressed in the differenti-
ated [4].
Bmi-1 functions as a transcriptional repressor that targets
the INK4a locus and is necessary for self-renewal in the
blood and brain. Parallel to these normal organ systems,
Bmi-1 can also play an integral role in the malignant
transformation of the HOX A9/MEIS – induced murine
leukemia model [13] as well as in tumors of neural origin
[15]. These findings highlight the notion that the molecu-
lar regulation of self-renewal can be observed in both nor-
mal and cancer stem cells. Our observation of Bmi-1,
SHH, Oct4, PSP and Snail expression only in the cancer
stem cell component of a human brain malignancy may
shed light on the dynamic nature of the cancer stem cell
Drug sensitivity of CD133 positive cancer stem cells derived from No. 377 Figure 4
Drug sensitivity of CD133 positive cancer stem cells derived from No. 377. Both CD133+ and CD133- tumor cells 
were collected from No. 377 by FACS sorting. 1 × 104 cells/well were plated in 96-well plate and treated with various concen-
trations of temozolomide, carboplatin, Taxol and VP16 for 48 hours in 10% FBS/DMEM/F-12 medium. * indicates p < 0.05 com-
pared to autologous CD133- cells. Data are representative of two independent experiments.Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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to exit the capacity to self renew as it differentiates into a
daughter cell.
Cancer stem cells may be responsible for the initiation
and maintenance of neoplastic tissue. Alternatively, neu-
ral progenitor or terminally differentiated cells may dedif-
ferentiate to a stem-like state to form the tumor initiating
cell. The tumor initiating and sustaining stem-like cells'
resistance to chemo- and radiation therapy, may explain
why such traditional therapies can shrink a tumor but
often cannot completely eradicate it resulting in eventual
recurrence[16]. In this study, we tested four common
chemotherapeutic agents on CD133 positive cancer stem
cells. Consistent with our hypothesis, CD133 positive
cancer stem cells are significantly resistant to four tested
chemotherapeutic agents, including temozolomide, car-
boplatin, VP16 and Taxol than autologous CD133 nega-
tive cells.
Temozolomide is a new oral alkylating agent that is
widely used for high-grade gliomas [17]. The cytotoxicity
of temozolomide is primarily due to the formation of O6-
methylguanine in DNA, which mispairs with thymine
during the next cycle of DNA replication [18]. Subsequent
futile cell cycles of DNA lead to mismatched repairs and
result in cancer cell death. [19]. Current available data
generated from investigations in cell lines and tumor sam-
ples, suggest that resistance to temozolomide is signifi-
Drug sensitivity of CD133 positive cancer stem cells derived from No. 1049 Figure 5
Drug sensitivity of CD133 positive cancer stem cells derived from No. 1049. Both CD133+ and CD133- tumor cells 
were collected from No. 1049 by FACS sorting. 1 × 104 cells/well were plated in 96-well plate and treated with various con-
centrations of temozolomide, carboplatin, Taxol and VP16 for 48 hours in 10% FBS/DMEM/F-12 medium. * indicates p < 0.05 
compared to autologous CD133- cells. Data are representative of two independent experiments.Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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cantly linked to MGMT-mediated DNA repair in high-
grade gliomas, primitive neuroectodermal tumors, and
ependymomas [20]. Our study showed CD133 positive
cells had significant resistance to temozolomide com-
pared to autologous CD133 negative cells, which was con-
sistent with the results of higher MGMT expression in
CD133 positive cells.
One of the important mechanisms of drug resistance is
the expression of ATP-binding cassette transporter pro-
tein, such as BCRP1. BCRP1 accounts for chemoresistance
of some clinical cancers including acute myeloid leuke-
mia, non-small cell cancer, and breast cancer. In both
breast carcinoma and acute myeloid leukemia, putative
cancer stem cells have been isolated and characterized.
The evidence suggests that the "side population (SP)"
phenotype is associated with high expression levels of
BCRP1 [6]. The exclusion of Hoechst 33342 dye defines
the pluripotential side population (SP) originally
reported in hematopoietic stem cells. Their high drug
efflux capacity correlates with the strong expression of the
drug-transporter protein BCRP1. Therefore, SP has
become a common approachto identify putative adult
stem cells [21] and cancer stem cells [12]. BCRP1 has been
shown to be specifically expressed in the fetal neural stem
cell by microarray and immunocytochemical analysis
[22]. We found that CD133 positive cells express higher
levels of BCRP1, which indicate that BCRP1 may also play
an important part in the drug resistance of CD133 positive
cells. BCRP1 over-expressing tumor cells, however, are
only resistant to mitoxantrone, adriamycin, daunoru-
bicin, etoposide, topotecan, and irinotecan. They are not
resistant to Taxol and vincristine [23]. In the present
study, CD133 positive cells derived from three cell lines
are all resistance to carboplatin and Taxol. Therefore, we
proposed that both anti-apoptosis factors and BCRP1
contribute the drug resistant property on CD133 positive
cancer stem cells.
Apoptosis mechanisms are hypothesized to play an
important role in the resistance of tumor cells to chemo-
therapy [24]. Most studies indicate that increased levels of
the anti-apoptotic protein Bcl-2 correlates with chemo-
therapy resistant disease and decreased overall survival
[25]. The inhibitor of apoptosis protein (IAPs) family are
anti-apoptotic proteins that bind and inhibit caspases 3, 7
and 9, and thereby prevent apoptosis [26]. Growing evi-
dence also indicates that IAPs also modulate cell division,
cell cycle progression and signal transduction pathways
[26]. In this study, we found that Bcl-2, FLIP, BCL-XL and
CD133 mRNA expression in primary (P) and recurrent (R) tumor tissue Figure 6
CD133 mRNA expression in primary (P) and recurrent (R) tumor tissue. Total RNA was extracted from both pri-
mary and recurrent tumor tissue derived from five patients. CD133 mRNA expression was measured by real-time qPCR. The 
relative CD133 mRNA level of recurrent tumor was presented as the fold increase compared to that of autologous primary 
tumor tissue (see Methods). Data are representative of two independent experiments.Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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all of the IAPs we tested, including Class I IAPs (XIAP,
cIAP1 and cIAP2); Class II IAP (NAIP) and Class III IAP
(survivin) expressed higher mRNA levels in CD133 posi-
tive cells than in CD133 negative cells. The data supports
the hypothesis that apoptosis pathways contribute to drug
resistance of CD133 positive cancer stem cells.
Bcl-2 promotes prolonged but not indefinite cell survival
under apoptotic stress from radiation, chemotherapy
drugs, and toxins [27]. The Bcl-2 family is made up of
both suppressors (e.g. Bcl-2, Bcl-XL  and MCL-1) and
inducers (e.g. Bax, Bad, Bak and Bid) of apoptosis. AML
leukemic cells recovered from patients with minimal
residual disease have demonstrated high levels of Bcl-2
and Bcl-XL [28], suggesting a significant role of these genes
in resistance to therapy.
ATRA has been shown to increase sensitivity to ARA-C by
downregulating Bcl-2 and Bcl-XL in vitro [29]. As a clinical
corollary, retinoids given with chemotherapy can improve
the survival of AML patients. Bcl-2 expression in patient
samples of AML cells correlated with decreased rates of
remission and event-free survival [30]. Furthermore, a low
Bcl-2/Bax ratio was associated with prolonged survival
[31]. These findings support the notion the inhibition of
apoptosis is directly associated with response to chemo-
therapy and hence clinical outcome.
Neural stem cells (NSCs) express the markers nestin and
CD133, and differentiate into neurons, astrocytes and oli-
godendrocytes at a clonal level [32]. An important charac-
teristic of NSCs, not fully understood, is their migratory
ability and their tropism to brain pathology. High expres-
sion levels of functional chemokine receptor CXCR4 have
been found on human neural stem cells [33]. These find-
ings suggest that CXCR4 may play a significant role in
directing NSC migration during CNS development. Simi-
lar to normal NSCs, CD133 positive cancer stem cells
showed 337.8 times increase on the expression levels of
CXCR4 than did CD133 negative cells, which suggests
CD133 positive cancer stem cells have higher capability of
migration and may play an important role in glioma inva-
sion.
Finally, CD133 expression levels are higher in recurrent
tumor tissue than in autologous primary tumor tissue,
which suggests that CD133 positive cancer stem cells may
play an important role in the tumor's ability to resist
chemotherapies and radiation therapy.
Taken together, because of higher BCRP1, MGMT and
IAPs levels, CD133 positive cancer stem cells may be
resistant to conventional chemotherapy and contribute to
disease relapse. Since normal tissue stem cells and cancer
stem cells have many similar properties, further studies
should focus on the difference between CD133positive
normal tissue stem cells versus  CD133 positive cancer
stem cells in order to find unique pathways to differenti-
ate these two cell populations. These differences may be
exploited with the aim of targeting the CD133 positive
cancer stem cell population either biochemically or
immunologically without harming normal tissue stem
cells. Delineating the molecular genetics and epigenetics
involved in the propagation and differentiation of these
stem cell populations will be useful in defining the thera-
peutic window to target only the cancer stem cell.
Materials and methods
Tumor specimens and primary cell culture
Glioblastoma specimens were obtained from patients
(with informed consents) via the Brain Tumor Registry
and were reviewed and released by a pathologist in the
operating room. Independent pathologists classified the
tumors by type and grade in accordance with the WHO
histological grading of central nervous system tumors. IRB
certified technicians processed the glioma tissues under
sterile conditions in a laminar flow hood. Tumor cells
were cultured in the following complete medium: Ham's
DMEM/F-12 with high glucose (Irvine scientific, Santa
Ana, CA), 10 mM HEPES (Invitrogen, Carlsbad, CA), 0.1
mg/ml Gentamicin (Invitrogen) and 10% heat-inacti-
vated FBS (Irvine Scientific, Santa Ana, CA). The cultured
cells were maintained for 3–6 passages. Three adult gliob-
lastoma primary cultured cell lines (No. 66, No. 377 and
No.1049) were used to isolate CD133 positive cancer
stem cells by FACS sorting for further experiments. In
order to investigate the capacity of self-newal and clono-
genic potential of CD133+ cell, a single isolated CD133
positive cancer stem cell was cultured in a defined serum-
free NSC medium[34] containing 20 ng/ml of basic
fibroblast growth factor (bFGF, Peprotech, Rocky Hill, NJ)
and 20 ng/ml of epidermal growth factor (EGF, Pepro-
tech). Both primary and recurrent glioblastoma tissue
from five different patients were used to analyze CD133
expression on tumor tissue.
Chemotherapeutic agents
Temozolomide was kindly supplied by the Schering-
Plough Research Institute (Kenilworth, NJ) and was dis-
solved in DMSO (Sigma Chemical Co., St Louis, MO) at
100 mM stock solution. Carboplatin, etoposide (VP16)
and paclitaxel (Taxol) were obtained from Sigma-Aldrich
(St. Louis, MO).
Immunofluoresence staining
To examine CD133 protein expression, a marker of cancer
stem cells, immunofluoresence staining was performed as
previously described [34]. Briefly, the cells growing in pre-
coated chamber slides were fixed with 2% paraformalde-
hyde for 15 min at room temperature, treated with 10%Molecular Cancer 2006, 5:67 http://www.molecular-cancer.com/content/5/1/67
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normal goat serum, and then stained with anti-CD133
antibody (rabbit polyclonal IgG; 1: 100; Abcam Inc, Cam-
bridge, MA). The primary antibodies were detected with
Alexa fluor 568 goat anti-rabbit IgG, (1: 1000; Molecular
Probes, Eugene, Oregon).
Flow cytometry analysis and FACS sorting CD133 positive 
cells
Tumor cells were collected and stained with anti-CD133
antibody (mouse monoclonal IgG1; 1: 10; Milteny Bio-
tec) or IgG1 isotype control antibody (BD Pharmingen,
San Diego, CA). After PE-ant-mouse IgG1 (BD Pharmin-
gen) staining for 30 min, CD133 staining was analyzed by
flow cytometry FACSCalibur (Becton Dickinson, San Jose,
CA). CD133 positive cells were sorted by DAKO cytoma-
tion (DAKO, Carpinteria, CA).
RNA isolation and cDNA synthesis
Total RNA was extracted from fresh tumor tissue and iso-
lated CD133 positive and CD133 negative cells using an
RNA4PCR kit (Amibion, Austin, TX) according to the
manufacturer's protocol. For cDNA synthesis, ~1 μg total
RNA was reverse-transcribed into cDNA using Oligo dT
primer and iScript cDNA synthesis kit reverse tran-
scriptase. cDNA was stored at -20°C for PCR.
Real-time Quantitative RT-PCR
Gene expression was quantified by real-time quantitative
RT-PCR using QuantiTect SYRB Green dye (Qiagen,
Valencia, CA). DNA amplification was carried out using
Icycler (BIO-RAD, Hercules, CA), and the detection was
performed by measuring the binding of the fluorescence
dye SYBR Green I to double-stranded DNA. All the primer
sets were provided by Qiagen (see Additional file 1). The
relative quantities of target gene mRNA against an internal
control, beta-actin, was possible by following a ΔCT
method. An amplification plot that had been the plot of
fluorescence signal vs. cycle number was drawn. The dif-
ference (ΔCT) between the mean values in the duplicated
samples of target gene and those of beta-actin were calcu-
lated by Microsoft Excel and the relative quantified value
(RQV) was expressed as  . The relative expression of
each gene or sample presented in this report was com-
pared to autologous CD133 negative cells or recurrent
tumor tissue.
Drug cytotoxicity assay
The number of viable cells following drug treatment was
assessed using a WST-1 Cell Proliferation Assay (Roche,
Indianapolis, IN). 1 × 104 cells/well were plated in 96-well
plates, then allowed to attach overnight and finally chem-
otherapeutic agents at various concentrations were added
for 48 h in 10% FBS/DMEM/F-12 culture medium. Four
hours prior to harvest, 20 μl/well of the reagent WST-1
was added and incubated for 1.5 h at 37°C. An increase in
the number of viable cells resulted in an increase in the
overall activity of mitochondrial dehydrogenases in the
sample with an ensuing increase in formazan dye forma-
tion. The quantity of formazan dye was quantified by
measuring the optical density of the dye solution at 450
nm with a scanning multiwell spectrophotometer (Molec-
ular Devices, Sunnyvale, CA) using 890 nm as the internal
reference [35]. All results in the study were based on at
least eight parallel measurements each time and each
measurement was repeated in up to two independent
experiments.
Statistical analysis
All the WST-1 assay results were analyzed by one way
analysis of variance (ANOVA) followed by post-hoc
(Tukey) tests using Sigmastat for Windows, version 2.03.
A level of P < 0.05 was considered statistically significant.
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